聚乙二醇干扰素α-2a单用及联用胸腺法新治疗慢性丙型病毒性肝炎效果分析被引量：4

Effects of peginterferon α-2a monotherapy and combined therapy of thymalfasin on treatment of chronic hepatitis C

在线阅读下载PDF

导出

摘要目的评价聚乙二醇干扰素α-2a(PegINFα-2a)单用及联用胸腺法新治疗慢性丙型病毒性肝炎的疗效和安全性。方法 74例慢性丙型病毒性肝炎患者随机分为两组:PegINFα-2a组;PegINFα-2a+胸腺法新组。比较两组治疗早期和治疗结束时生物化学应答率和病毒学应答率、持续生物化学应答率和复发率、持续病毒学应答率和复发率。结果 PegINFα-2a组治疗早期生物化学应答率、治疗结束时生物化学应答率、持续生物化学应答率和复发率分别为50.0%、76.2%、78.6%和15.6%;治疗早期病毒学答率、治疗结束时病毒学应答率、持续病毒学应答率和复发率分别为47.6%、76.2%、73.8%和15.6%;PegINFα-2a联合胸腺法新治疗组治疗早期生物化学应答率、治疗结束时生物化学应答率、持续生物化学应答率和复发率分别为53.0%、93.8%、96.9%和0%;治疗早期病毒学应答率、治疗结束时病毒学应答率、持续病毒学应答率和复发率分别为50.0%、93.8%、93.8%和0%。两组治疗早期各指标无统计学差异(P>0.05),治疗结束时各指标有统计学差异(P<0.05)。结论 PegINFα-2a能有效治疗慢性丙型病毒性肝炎,联用胸腺法新能增强疗效。 Objetive To evaluate the effects and safety of peginterferon α-2a monotherapy and combined therapy of thymalfasin for the treatment of chronic hepatitis C. Methods Seventy-four chronic hepatitis C patients were assigned randomly into two groups：peginterferon α-2a; peginterferon α-2a ＋ thymalfasin. Early biochemical response rates,end of treatment biochemical response, sustainable biochemical response, biochemical recurrence rates, early virological response rates,end of treatment virological response,sustainable virological response, virological recurrence rates,rates of adverse effects were analyzed. Results In the peginterferon α-2a group,early biochemical response rates,end of treatment biochemical response, sustainable biochemical response, biochemical recurrence rates were 50.0%,76.2%,78.6% and 15.6% respectively;early virological response rates,end of treatment virological response, sustainable virological response,virological recurrence rates were 47.6%,76.2%,73.8% and 15.6% respectively; In the peginterferon α-2a ＋ thymalfasin group, early biochemical response rates, end of treatment biochemical response, sustainable biochemical response, biochemical recurrence rates were 53.0%, 93.8%, 96.9% and 0% respectively, early virological response rates, end of treatment virological response, sustainable virological response, virological recurrence rates were 50.0%,93.8%, 93.8% and 0% respectively. There were statistical differences between the parameters at the end of the treatment（P〈0.05）, but without statistical differences between the parameters of the early treatment（P〉0.05）. Conclusion Peginterferonalf α-2a is effective on the treatment of chronic hepatitis C, combined therapy of thymalfasin can improve the therapeutic effects.

作者王琼王璟邓菁刘芳刘中文王桂良

机构地区湖南省攸县人民医院消化内科江西省萍乡市人民医院消化内科

出处《中国现代医生》 2016年第10期37-40,共4页 China Modern Doctor

关键词丙型病毒性肝炎聚乙二醇干扰素胸腺法新效果 Hepatitis C Peginterferon Thymalfasin Effects

分类号 R512.63 [医药卫生—内科学]

作者简介通讯作者

引文网络
相关文献

参考文献15

1Liang TJ,Ghany MG. Current and future therapies for hepatitis C virus infection[J]. N Engl J Med,2013,368(20) : 1907-1917.
2Robert D Allison,Xin Tong,Anne C,et al. Moorman. in- creased incidence of cancer and cancer-related mortality among persons with chronic hepatitis C infection,2006- 2010[J]. J Hepatol, 2015,63 ( 1 ) : 822-828.
3Gibbert K, Schlaak JF, Yang D, et al. IFN-c subtypes : Distinct biological activities in anti-viral therapy[J]. Br J Pharmaeol, 2013,168(5) :1048-1058.
4Conversano C,Carmassi C,Carlini M,et al. Interferon o therapy in patients with chronic hepatitis C infection: Quality of life and depression[J]. Hematol Rep, 2015,7 (1) : 5632.
5Tuthill C,Rios I,De Rosa A,et al. Thymosin cd continues to show promise as an enhancer for vaccine response [J]. Ann N Y Acad Sci, 2012, 1270( 1 ) : 21-27.
6Webster DP,Klenerman P,Dusheiko GM. Hepatitis C[J]. Lancet, 2015,385(9116) : 1643-1649.
7Helm MH,Thimme R. Innate and adaptive immune re- sponses in HCV infections[J]. J Hepatol,2014,61(1S): S14-$25.
8Bull RA,Leung P,Gaudieri S,et al. Transmitted/founder viruses rapidly escape from CD8+ T cell responses in acute hepatitis C virus infection[J]. J Virol,2015,89(10):5478- 5490.
9Dustin LB,Cashman SB,Laidlaw SM. Immune control and failure in HCV infection-tipping the balance[J]. J Leukoc Biol, 2014,96(4) : 535-548.
10Homer SM,Naggie S. Successes and Challenges on the road to cure hepatitis C[J]. PLoS Pathog, 2015,11 (6) : e1004854.